Amneal Pharmaceuticals (AMRX) announced that it has received FDA approval of its new drug application, or NDA, for Pyridostigmine Bromide Extended-Release Tablets USP 105 mg.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals price target raised to $12 from $10 at Truist
- Amneal and Metsera Partner to Target Obesity Market
- Amneal Pharmaceuticals and Metsera to codevelop weight loss medicines
- Amneal Pharmaceuticals debuts Crexont extended-release for Parkinson’s treatment
- Amneal Pharmaceuticals upgraded to Neutral from Underweight at JPMorgan